<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302458</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-001812</org_study_id>
    <nct_id>NCT00302458</nct_id>
  </id_info>
  <brief_title>A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Crossover Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, five-period crossover study to
      examine the likability of a repeated administration of immediate release methylphenidate
      hydrochloride (IR-MPH 40 mg) and OROS®-MPH (CONCERTA® 72 mg) in healthy adults. Hypotheses
      are as follows:

        -  Hypothesis 1: the subjective feelings of detection and likeability will be greater for
           periods of IR-MPH administration than after OROS-MPH administration irregardless of
           sequence;

        -  Hypothesis 2: the greater ratings of feelings of detection and likeability will be
           associated with the periods of most rapid change in plasma d-MPH and not with the
           magnitude of plasma d-MPH concentration (other than the OROS-MPH to IR-MPH condition in
           which they coincide), and

        -  Hypothesis 3: the subjective feelings of dislike will be greatest for the two conditions
           in which IR-MPH is the second condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of this study is to assess whether the abuse liability potential of delayed,
      repeated administrations of different formulations of MPH is moderated by the oral delivery
      system in which a delivery system with slower onset may be safer than one with more rapid
      early release. To this end, the investigators will compare repeated administration of orally
      administered, therapeutic doses of a short (IR-MPH) and a long-acting formulation of MPH
      (OROS-MPH) in the following areas:

        1. pharmacokinetic profile of MPH assessing rate of onset of MPH action (indexed through
           change in plasma level) and

        2. abuse liability (indexed through detection and likeability).

      The investigators will test all combinations of initial administration and then delayed
      (repeated) administration of the two formulations: IR-MPH to IR-MPH; IR-MPH to OROS-MPH;
      OROS-MPH to IR-MPH; OROS-MPH to OROS-MPH, and placebo to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration of d-Methylphenidate</measure>
    <time_frame>4 hours</time_frame>
    <description>Objective measure determined from blood samples, measured 4 hours after the dose</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OROS-MPH + OROS-MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR MPH + IR MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plabebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered during the first part of the day, and again during the second part of the day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OROS MPH+ IR MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR MPH + OROS MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS-Methylphenidate</intervention_name>
    <description>Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules</description>
    <arm_group_label>OROS-MPH + OROS-MPH</arm_group_label>
    <arm_group_label>OROS MPH+ IR MPH</arm_group_label>
    <arm_group_label>IR MPH + OROS MPH</arm_group_label>
    <other_name>Concerta</other_name>
    <other_name>OROS MPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Release Methylphenidate</intervention_name>
    <description>Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules</description>
    <arm_group_label>IR MPH + IR MPH</arm_group_label>
    <arm_group_label>OROS MPH+ IR MPH</arm_group_label>
    <arm_group_label>IR MPH + OROS MPH</arm_group_label>
    <other_name>IR MPH</other_name>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered during the first part of the day, and again during the second part of the day.</description>
    <arm_group_label>Plabebo + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or non-pregnant, non-lactating females. With the exception of women who have
             been post-menopausal for a minimum of 12 months prior to screening and those who have
             undergone hysterectomy or bilateral oophorectomy, all female subjects must have a
             negative urine pregnancy test at both screening and at each admission to the research
             unit. All male and female subjects must have used a medically acceptable form of birth
             control for at least one month prior to screening and be willing to continue use
             during the study. Medically acceptable forms of birth control include abstinence,
             hormonal contraceptives, diaphragm with spermicide, condom with spermicide,
             intrauterine device, or surgical sterilization (including vasectomy of male
             partner[s]).

          2. Eighteen (18) to 45 years of age, inclusive

          3. Based on medical history, limited physical examination (neurologic and cardiac) and/or
             lab results, are considered healthy and free of any conditions that may interfere with
             participation in the study. Any abnormalities at screening on results of
             electrocardiogram (ECG) or any laboratory test must be determined to be not clinically
             significant by an investigator.

          4. Agree to not use prescription stimulants (except for the study medication) during the
             study

          5. Have venous access sufficient for blood sampling as determined by clinical examination

          6. Weigh at least 100 pounds at screening

          7. Agree and are available to return to the study center for five full-day (approximately
             18 hours) study visits held five to 30 days apart within a 22-week period, and willing
             to complete all protocol-specified assessments.

          8. Able to read and comprehend English

        Exclusion Criteria:

          1. Marked anxiety, tension, and agitation since the drug may aggravate these symptoms

          2. Known hypersensitivity to methylphenidate or other components of Concerta or Ritalin

          3. Subjects with glaucoma

          4. Motor tics or with a family history or diagnosis of Tourette's syndrome

          5. Treated with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation
             of treatment with MAOIs

          6. Presence or history of any medically diagnosed, clinically significant Axis I
             psychiatric disorder (including substance use disorders, bipolar disorder, any
             psychotic disorder)

          7. Scores of Baseline Scales:

               -  Hamilton Depression Scale &gt; 17 (out of a possible 67 on the 21-item scale)
                  (Hamilton 1960)

               -  Beck Depression Inventory &gt; 19 (out of a possible 63 on the 21-item scale) (Beck
                  et al 1961)

               -  Hamilton Anxiety Scale &gt; 21 (out of a possible 56 on the 14-item scale) (Hamilton
                  1959)

          8. Any clinically significant chronic disease or unstable medical abnormality by history
             or physical examination, including hypertension, hyperthyroidism, a seizure disorder,
             history of myocardial infarction or stroke, or history of cardiac arrhythmia or heart
             murmur (other than uncomplicated mitral valve prolapse)

          9. Clinically significant abnormal baseline laboratory values which include the
             following:

               -  Values &gt; 20% above the upper range of the laboratory standard of a basic
                  metabolic screen and complete blood count

               -  Exclusionary blood pressure &gt; 140 (systolic) and 90 (diastolic).

               -  Exclusionary ECG parameters: QTC &gt; 460 msec, QRS &gt; 120 msec, and PR &gt; 200 msec.
                  Subjects having ECG evidence of ischemia or arrhythmia as reviewed by an
                  independent cardiologist

         10. Currently taking or require any of the following medications:

               -  Clonidine or other alpha-2 adrenergic receptor agonists

               -  Tricyclic antidepressants

               -  Selective serotonin reuptake inhibitors (SSRIs)

               -  Theophylline

               -  Coumarin anticoagulants

               -  Anticonvulsants

               -  Prescription stimulants

         11. Have taken an SSRI in the 35 days before initiation of the study medication

         12. Currently physically dependent on benzodiazepines, opiates or alcohol as determined by
             clinical evaluation or positive urine drug screen at screening

         13. Preexisting severe gastrointestinal narrowing (pathologic or iatrogenic, for example:
             small bowel inflammatory disease, &quot;short gut&quot; syndrome due to adhesions or decreased
             transit time, past history of peritonitis, cystic fibrosis, chronic intestinal
             pseudoabsorption, or Meckel's diverticulum)

         14. Unable to swallow the study medication whole

         15. Have had a significant blood loss (&gt; 500 mL) or donated blood in the 30 days preceding
             dosing

         16. Have a positive urine drug screen at screening

         17. Have taken an investigational medication or product within the past 30 days

         18. Have taken prescription medications (with the exception of birth control methods)
             within seven days of screening or is anticipated to need any medications,
             over-the-counter products (other than acetaminophen), or herbal supplements during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Spencer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <results_first_submitted>November 18, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2014</results_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thomas J. Spencer, MD</investigator_full_name>
    <investigator_title>Assistant Director of the Clinical and Research Program in Pediatric Psychopharmacology</investigator_title>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 2005 to 2007 at Massachusetts General Hospital and were recruited using IRB approved postings through web and email.</recruitment_details>
      <pre_assignment_details>Based on a comprehensive screening, subjects who did not meet eligibility criteria for the study were excluded. Others withdrew or were lost to follow-up before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers each received IR MPH, Oros MPH, and matched placebo (at four separate study visits) in a four way crossover design.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible after screening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject was ineligible, one subject was lost to follow-up, one withdrew, and twenty six subjects completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers each received IR-MPH, OROS-MPH, and matched placebo (in four separate visits) in a four way crossover design.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.86" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration of d-Methylphenidate</title>
        <description>Objective measure determined from blood samples, measured 4 hours after the dose</description>
        <time_frame>4 hours</time_frame>
        <population>All subjects received each combination of medications on a separate day (total= 5 days)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo- Placebo</title>
            <description>Healthy volunteers received a placebo, followed by a placebo four hours later</description>
          </group>
          <group group_id="O2">
            <title>IR-MPH + OROS MPH</title>
            <description>Healthy volunteers received a dose of Immediatate Release Methylphenidate at hour 0, followed by a dose of OROS-Methylphenidate four hours later</description>
          </group>
          <group group_id="O3">
            <title>IR-MPH +IR-MPH</title>
            <description>Healthy volunteers received a dose of Immediatate Release Methylphenidate at hour 0, followed by a dose of Immediate Release Methylphenidate four hours later</description>
          </group>
          <group group_id="O4">
            <title>OROS-MPH+OROS-MPH</title>
            <description>Healthy volunteers received a dose of OROS-Methylphenidate at hour 0, followed by a dose of OROS-Methylphenidate four hours later</description>
          </group>
          <group group_id="O5">
            <title>OROS-MPH+ IR-MPH</title>
            <description>Healthy volunteers received a dose of OROS-Methylphenidate at hour 0, followed by a dose of Immediate Release Methylphenidate four hours later</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration of d-Methylphenidate</title>
          <description>Objective measure determined from blood samples, measured 4 hours after the dose</description>
          <population>All subjects received each combination of medications on a separate day (total= 5 days)</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="15.06" spread="5.0"/>
                    <measurement group_id="O3" value="25.34" spread="7.3"/>
                    <measurement group_id="O4" value="20.34" spread="6.4"/>
                    <measurement group_id="O5" value="28.79" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers each received IR MPH, Oros MPH, and matched placebo (at four separate study visits) in a four way crossover design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aware of heartbeat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heart Racing</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Stomach Ache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="27" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heavy head</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Jittery</sub_title>
                <counts group_id="E1" events="33" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" events="22" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sweaty</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tingling in hands</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tingling in Head</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tired</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Head Pressure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Loss</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heavy limbs</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Jaw Clenching</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Limb Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fogginess in head</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Unfocused</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Spencer</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1731</phone>
      <email>spencer@helix.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

